Eicosenoyl Sphingomyelin
Eicosenoyl sphingomyelin is a specific type of sphingolipid, which are complex lipids that are fundamental components of cell membranes in all living organisms. These molecules are particularly abundant in the nervous system, where they contribute significantly to the structure and function of myelin, the insulating sheath around nerve fibers. Sphingolipids, in general, are not merely structural elements but also act as crucial signaling molecules involved in various cellular processes.
Biological Basis
Section titled “Biological Basis”Eicosenoyl sphingomyelin is characterized by its specific fatty acid component: eicosenoic acid, a monounsaturated fatty acid containing 20 carbon atoms. This fatty acid is attached to the sphingosine backbone, forming the complete sphingomyelin molecule. The unique fatty acid composition of eicosenoyl sphingomyelin can influence the physical properties of cell membranes, such as fluidity and permeability, thereby affecting membrane protein function and cell signaling. These lipids are synthesized through enzymatic pathways primarily in the endoplasmic reticulum and Golgi apparatus and are then distributed to different cellular compartments, including the plasma membrane, endosomes, and lysosomes. They participate in key biological functions such as cell growth, differentiation, adhesion, and programmed cell death.
Clinical Relevance
Section titled “Clinical Relevance”Alterations in the metabolism or levels of eicosenoyl sphingomyelin, and sphingomyelins broadly, are associated with a range of human diseases. For instance, disruptions in sphingolipid pathways are implicated in several neurodegenerative disorders, including Alzheimer’s disease and Parkinson’s disease, as well as in lysosomal storage disorders like Niemann-Pick disease, where defective enzyme activity leads to the accumulation of sphingomyelin within cells. Furthermore, imbalances in sphingomyelin composition have been observed in cardiovascular diseases, potentially contributing to atherosclerosis and plaque development, and in metabolic conditions such as obesity and type 2 diabetes. Understanding these associations can shed light on disease mechanisms and identify potential biomarkers.
Social Importance
Section titled “Social Importance”The study of eicosenoyl sphingomyelin and its roles in human physiology and pathology carries significant social importance. Research into these complex lipids provides insights into fundamental cellular processes and how their dysregulation contributes to disease. This knowledge is critical for developing new diagnostic tools, identifying therapeutic targets, and designing novel treatments for a variety of conditions, including neurological, cardiovascular, and metabolic diseases. By advancing our understanding of sphingolipid biology, researchers aim to improve health outcomes and enhance the quality of life for individuals affected by these challenging disorders.
Limitations
Section titled “Limitations”Methodological and Statistical Constraints
Section titled “Methodological and Statistical Constraints”The interpretability of findings for complex traits like eicosenoyl sphingomyelin is subject to several methodological and statistical limitations inherent in genome-wide association studies (GWAS). Many studies rely on moderate-sized cohorts, which may limit the statistical power to detect novel genetic variants with smaller effect sizes or to comprehensively study candidate genes, necessitating larger sample sizes for robust discovery[1], [2]. [3]Furthermore, the coverage of single nucleotide polymorphisms (SNPs) in some initial GWAS, often using 100K arrays or subsets of HapMap SNPs, might be insufficient to capture all true associations or provide complete coverage of gene regions, potentially leading to missed signals[2]. [3] Errors introduced during genotype imputation, estimated to be between 1.46% and 2.14% per allele in some instances, could also affect the accuracy of associations. [4]
The reliance on fixed-effects meta-analysis, while common, assumes a consistent effect size across studies and may not adequately account for potential heterogeneity between cohorts, which could influence the combined effect estimates[5]. [6] Although genomic control corrections are applied to mitigate population substructure effects, the underlying assumptions of such methods may not fully address all sources of bias [6]. [7]Additionally, some analyses are performed in a sex-pooled manner, potentially overlooking genetic variants that exert sex-specific effects on eicosenoyl sphingomyelin levels, thereby reducing the ability to identify all relevant associations.[3] Ultimately, many GWAS findings are considered hypotheses requiring independent replication in other cohorts and functional validation to establish true genetic associations [2], [8]. [3]
Phenotypic Characterization and Measurement Challenges
Section titled “Phenotypic Characterization and Measurement Challenges”Accurate and consistent phenotypic characterization is critical for robust genetic association studies, and several challenges exist in this domain. When phenotypes, such as lipid measures or other biomarkers, are averaged over extended periods (e.g., twenty years) or across multiple examinations using different equipment, this can introduce misclassification and potentially mask age-dependent genetic effects. [9] While covariate adjustments for factors like age, sex, and ancestry-informative principal components are essential to control for known confounders, they may also inadvertently obscure or mediate the effects of some genetic loci, making it challenging to discern direct versus indirect genetic influences [1]. [3] The exclusion of individuals on lipid-lowering therapies is a necessary step to isolate genetic effects on baseline levels, but it may limit the generalizability of findings to the broader population that includes treated individuals [1]. [4]
Furthermore, the specific statistical adjustments applied, such as log-transformation for skewed distributions like triglycerides, aim to meet model assumptions but can alter the interpretation of effect sizes. [6] The assumption of an additive mode of inheritance in many GWAS models may not always fully capture the true genetic architecture of complex traits, potentially missing non-additive effects [1]. [6] The variability in study-specific criteria for genotyping quality control and analysis, while standardized during meta-analysis, could still introduce subtle differences in initial data quality and processing. [5]These variations in phenotypic definition and analytical approaches can impact the precision and comparability of genetic associations identified for eicosenoyl sphingomyelin.
Generalizability and Remaining Knowledge Gaps
Section titled “Generalizability and Remaining Knowledge Gaps”A significant limitation for understanding the genetic basis of eicosenoyl sphingomyelin is the predominant focus of many initial GWAS on populations of European ancestry. While some studies attempt to extend findings to multiethnic samples, the vast majority of participants in the discovery and replication phases are of self-reported European descent[1], [6], [10]. [9] This demographic bias means that the generalizability of identified genetic associations to other ethnic groups remains largely unknown, limiting the broader applicability of these findings. [9] Differences in allele frequencies, linkage disequilibrium patterns, and environmental exposures across diverse populations could lead to distinct genetic architectures for complex traits, emphasizing the need for more inclusive studies.
Beyond population-specific findings, the current body of research often provides initial genetic associations without fully elucidating the complex interplay of environmental factors or gene-environment interactions. While covariates are used to adjust for some environmental influences, a comprehensive understanding of how specific environmental exposures modify genetic predispositions to affect eicosenoyl sphingomyelin levels is largely unaddressed in the provided context. The studies primarily identify statistical associations, underscoring that these findings serve as hypotheses for future research; the ultimate validation requires extensive functional studies to determine the biological mechanisms by which identified genetic variants influence the trait[8]. [3]Thus, significant knowledge gaps remain regarding the full etiological pathways, the contribution of rare variants not captured by common SNP arrays, and the precise environmental modifiers affecting eicosenoyl sphingomyelin levels.
Variants
Section titled “Variants”The _CERS4_ (Ceramide Synthase 4) gene plays a pivotal role in the complex process of lipid metabolism, specifically in the synthesis of ceramides. These ceramides are essential components of cellular membranes and act as crucial signaling molecules within the body . _CERS4_is particularly known for its specificity in generating ceramides that incorporate very long-chain fatty acids, notably the 20-carbon eicosenoyl fatty acid. These eicosenoyl ceramides serve as direct precursors for the formation of eicosenoyl sphingomyelin, a significant sphingolipid found abundantly in nerve tissues and other cell membranes, where it contributes to membrane fluidity, cell recognition, and signal transduction . Genetic variations within_CERS4_can therefore influence the precise composition and abundance of these critical lipid species, potentially affecting various physiological functions and disease susceptibility, a concept often explored in genome-wide association studies.[8]
Variants such as *rs62126382 * and *rs7248003 *are single nucleotide polymorphisms (SNPs) located within or near the_CERS4_ gene, and they are hypothesized to influence its activity or expression levels. These common genetic changes may subtly alter the efficiency with which _CERS4_produces very long-chain ceramides, thereby impacting the overall pool of eicosenoyl sphingomyelin in cells and tissues . Such alterations can have downstream effects on metabolic pathways, potentially affecting cell growth, inflammation, and the structural integrity of membranes. Understanding how these variants modulate_CERS4_ function is key to deciphering their contribution to individual differences in lipid profiles and associated health outcomes .
Another notable variant, *rs148417916 *, may represent a more impactful change within the _CERS4_ gene, possibly affecting the enzyme’s protein structure or catalytic efficiency. A significant alteration in _CERS4_function due to this variant could lead to pronounced shifts in the cellular balance of eicosenoyl sphingomyelin and other very long-chain sphingolipids . Such a disruption might contribute to conditions characterized by abnormal lipid accumulation or impaired cellular signaling, given the vital roles of eicosenoyl sphingomyelin in neurological function and overall cellular homeostasis. Research into these types of variants helps to illuminate the genetic underpinnings of complex traits and metabolic disorders related to sphingolipid metabolism .
Key Variants
Section titled “Key Variants”| RS ID | Gene | Related Traits |
|---|---|---|
| rs62126382 rs7248003 rs148417916 | CERS4 | sphingomyelin measurement gout glycosyl ceramide (d18:1/20:0, d16:1/22:0) measurement glycosyl-N-stearoyl-sphingosine (d18:1/18:0) measurement serum metabolite level |
Classification, Definition, and Terminology
Section titled “Classification, Definition, and Terminology”Definition and Lipid Nomenclature
Section titled “Definition and Lipid Nomenclature”Sphingomyelins represent a significant class of lipids identified as “metabolic traits” within serum analyses. [11]The term ‘eicosenoyl sphingomyelin’ describes a specific sphingomyelin molecule characterized by the incorporation of an eicosenoyl fatty acyl side chain. Lipid side chain composition is systematically abbreviated as Cx:y, where ‘x’ denotes the total number of carbons in the fatty acid chain and ‘y’ specifies the number of double bonds present. [11] This standardized nomenclature is essential for precisely defining and distinguishing the diverse array of fatty acid components that constitute complex lipids.
Classification within Metabolite Profiles
Section titled “Classification within Metabolite Profiles”Sphingomyelins are classified as key components within the broader category of “metabolite profiles” found in human serum.[11]Specific variants, such as “Sphingomyelin SM” and “Sphingomyelin SM(OH, COOH) C18:2,” are recognized as “genetically determined metabotypes” in genetic studies.[11] These lipids are investigated alongside other lipid classes, including phosphatidylcholines (PC aa, PC ae) and phosphatidylethanolamines (PE aa), which are further distinguished by the type of bonds in their glycerol moiety. [11]This comprehensive classification aids in understanding the intricate metabolic pathways and their genetic underpinnings.
Measurement Approaches and Scientific Significance
Section titled “Measurement Approaches and Scientific Significance”The concentrations of sphingomyelins are ascertained through precise measurement approaches applied to serum samples, typically collected after an overnight fast. [12] These quantitative measurements are fundamental for identifying “metabolic traits” in large-scale investigations, such as genome-wide association studies (GWAS). [11] The identification of specific sphingomyelins as “genetically determined metabotypes” offers crucial insights into the biochemical mechanisms influenced by genetic variations, thereby contributing to the understanding of conditions like polygenic dyslipidemia and uncovering potential new biological pathways for further research. [11]
Biological Background of Eicosenoyl Sphingomyelin
Section titled “Biological Background of Eicosenoyl Sphingomyelin”Sphingomyelin Biosynthesis and Interconnected Lipid Metabolism
Section titled “Sphingomyelin Biosynthesis and Interconnected Lipid Metabolism”Eicosenoyl sphingomyelin is a type of sphingolipid, characterized by a sphingoid base linked to a fatty acid, specifically an eicosenoyl (C20:1) chain, and a phosphocholine head group. The synthesis of sphingomyelin is closely linked to the broader landscape of glycerophospholipid metabolism, as sphingomyelin can be produced through the enzymatic action of sphingomyelin synthase, which utilizes phosphatidylcholine as a substrate.[11]Phosphatidylcholines themselves are synthesized via the Kennedy pathway, where two fatty acid moieties are attached to glycerol 3-phosphate, followed by dephosphorylation and the addition of a phosphocholine group.[11]This metabolic interplay highlights how the availability and composition of phosphatidylcholines directly influence sphingomyelin synthesis and its overall cellular balance.[13]
The fatty acid components of these complex lipids, such as the eicosenoyl chain, are derived from various metabolic pathways. While some fatty acids like palmitic (C16:0), stearic (C18:0), and oleic (C18:1) acids can be synthesized de novo within the human body, long-chain polyunsaturated fatty acids (PUFAs) must be produced from essential dietary fatty acids. [11]For example, linoleic acid (C18:2) initiates the omega-6 fatty acid synthesis pathway, and alpha-linolenic acid (C18:3) initiates the omega-3 pathway, leading to the production of longer and more desaturated fatty acid chains.[11] The precise composition of these fatty acid side chains, abbreviated as Cx:y (where x is carbon number and y is double bonds), is crucial for lipid function and is influenced by specific enzymatic reactions. [11]
Genetic Regulation of Fatty Acid Desaturation
Section titled “Genetic Regulation of Fatty Acid Desaturation”A key genetic determinant influencing the fatty acid composition of lipids, including those found in sphingomyelin, is the fatty acid desaturase (FADS) gene cluster. Specifically, the FADS1 gene plays a critical role in the synthesis of long-chain polyunsaturated fatty acids by encoding the fatty acid delta-5 desaturase enzyme. [11] Common genetic variants within the FADS1/FADS2 gene cluster, and their associated haplotypes, are known to influence the fatty acid composition of phospholipids. [14] These genetic variations can modify the efficiency of the delta-5 desaturase reaction, thereby altering the availability of various polyunsaturated fatty acids for incorporation into complex lipids. [11]
The impact of FADS1genotype extends beyond the direct production of polyunsaturated fatty acids, affecting the homeostasis of other lipid classes. For instance, studies have shown a negative association between specific sphingomyelin concentrations (e.g., SM C22:2, SM C24:2, SM C28:4) and theFADS1 genotype. [11] This suggests that changes in the efficiency of the FADS1enzyme, which primarily affects phosphatidylcholine fatty acid composition, can indirectly lead to altered sphingomyelin levels due to the metabolic interconversion between these lipid classes.[11] This highlights a complex regulatory network where genetic variations in one pathway can ripple through interconnected metabolic routes, influencing the levels of diverse biomolecules.
Cellular Lipid Homeostasis and Regulatory Networks
Section titled “Cellular Lipid Homeostasis and Regulatory Networks”The balance of various lipid classes, including eicosenoyl sphingomyelin, is tightly controlled at the cellular level to maintain membrane integrity and facilitate signaling processes. Cellular functions related to lipid metabolism involve a variety of key biomolecules, such as critical enzymes like sphingomyelin synthase and fatty acid desaturases, which directly catalyze lipid transformations.[11]The overall cellular lipid environment, including the availability of specific fatty acids and glycerophospholipids, is a critical factor influencing sphingomyelin synthesis and its subsequent cellular roles. Any modification in the efficiency of enzymes like the fatty acid delta-5 desaturase can lead to an overall changed balance in glycerophospholipid metabolism, thereby impacting the production and composition of sphingomyelins.[11]
Regulatory networks involving gene expression patterns and protein activity further ensure lipid homeostasis. For example, the synthesis of fatty acids involves enzymes like acyl-malonyl acyl carrier protein-condensing enzyme, which are fundamental to building lipid structures. [15] The dynamic interplay between de novo synthesis, dietary intake of essential fatty acids, and enzymatic modification ensures that cells have the necessary lipid building blocks. Disruptions in this intricate balance, whether due to genetic predispositions or environmental factors, can lead to altered lipid profiles and potentially impact cellular function.
Systemic Consequences of Lipid Dysregulation
Section titled “Systemic Consequences of Lipid Dysregulation”The concentrations of various lipids, including sphingomyelins, in systemic circulation (e.g., human serum) are reflective of whole-body lipid metabolism and can have systemic consequences. [11]Dysregulation in sphingomyelin levels, often as a result of altered phosphatidylcholine homeostasis influenced by genes likeFADS1, contributes to the broader spectrum of lipid profile variations observed in populations. [11] These systemic lipid profiles are complex and influenced by many genetic loci, contributing to conditions like polygenic dyslipidemia. [1]While specific tissue or organ-level effects of eicosenoyl sphingomyelin are not explicitly detailed, the measurement of its concentrations in serum suggests its relevance to systemic metabolic health.
Other genes involved in lipid metabolism, such as APOC3, are known to influence plasma lipid profiles, with null mutations in APOC3 conferring a favorable plasma lipid profile and apparent cardioprotection. [16] APOC3is a potent hyperlipidemia-inducing factor and an inhibitor of lipoprotein lipase, which is crucial for triglyceride breakdown.[17] Similarly, HMGCR is critical for cholesterol synthesis and its variants are associated with LDL-cholesterol levels. [18] Although these examples illustrate the systemic impact of lipid-related genes, the specific link between APOC3 or HMGCRand eicosenoyl sphingomyelin is not detailed in the provided context, emphasizing that lipid metabolism is a highly interconnected system where alterations in one component can have widespread effects.
Pathways and Mechanisms
Section titled “Pathways and Mechanisms”Lipid Biosynthesis and Fatty Acid Desaturation
Section titled “Lipid Biosynthesis and Fatty Acid Desaturation”The synthesis of eicosenoyl sphingomyelin, like other complex lipids, relies on the availability and processing of its fatty acid components. The human body can synthesize un- and monounsaturated fatty acids, such as palmitic (C16:0), stearic (C18:0), and oleic (C18:1) acids,de novo. However, long-chain polyunsaturated fatty acids (PUFAs) are derived from essential fatty acids like linoleic acid (C18:2) in the omega-6 pathway and alpha-linolenic acid (C18:3) in the omega-3 pathway.[11] This critical desaturation process is mediated by enzymes encoded by the FADS1 and FADS2 gene cluster, which introduce double bonds into fatty acyl chains, influencing the overall fatty acid composition of phospholipids. [11]
While the specific pathway for eicosenoyl sphingomyelin synthesis is not explicitly detailed, the general principles of membrane lipid biosynthesis involve the assembly of fatty acid moieties with a backbone structure and a head group.[13]For instance, the Kennedy pathway, responsible for producing glycerol-phosphatidylcholines, illustrates how fatty acid residues are combined with a glycerol 3-phosphate and a phosphocholine moiety.[11] The regulation of these biosynthetic steps, including the precise elongation and desaturation of fatty acids to yield components like the eicosenoyl (C20:1) chain, is fundamental for maintaining the structural and functional integrity of cellular membranes.
Lipid Transport and Catabolism
Section titled “Lipid Transport and Catabolism”The steady-state levels of eicosenoyl sphingomyelin and other lipids are dynamically controlled by pathways governing their transport and catabolism. Lipid catabolism is influenced by various regulatory proteins, such as angiopoietin-like protein 4 (ANGPTL4), which acts as a potent hyperlipidemia-inducing factor by inhibiting lipoprotein lipase, an enzyme crucial for hydrolyzing triglycerides in circulating lipoproteins.[17] Similarly, apolipoprotein CIII (APOCIII) can reduce the fractional catabolic rate of very low-density lipoproteins, contributing to hypertriglyceridemia. [19]
The breakdown of complex lipids, including sphingomyelins, also involves specialized enzymes. For example, members of the patatin-like phospholipase family (PNPLA) contribute to lipid hydrolysis, playing a role in the turnover of lipid species within cells and in circulation. [20] The coordinated action of these proteins and enzymes in lipid transport and degradation ensures the continuous remodeling of cellular membranes and the efficient recycling or disposal of lipid components. This balance is crucial for maintaining overall lipid homeostasis and preventing the accumulation of potentially harmful lipid species.
Genetic and Post-Translational Regulation of Lipid Enzymes
Section titled “Genetic and Post-Translational Regulation of Lipid Enzymes”The pathways involved in lipid metabolism are subject to sophisticated regulatory mechanisms, including control at the genetic and post-translational levels. Gene expression, such as that of the Adiponutringene in human adipose tissue, is regulated by metabolic signals like insulin and glucose, reflecting the body’s energy status and influencing lipid storage and mobilization . Moreover, common genetic variants, including single nucleotide polymorphisms (SNPs), can impact critical processes like alternative splicing of mRNA, as observed forHMGCR, thereby potentially altering the structure or function of enzymes central to lipid synthesis. [18]
Post-translational modifications provide another layer of intricate control over lipid-metabolizing enzymes. The stability and activity of enzymes like 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), a key enzyme in cholesterol synthesis, can be influenced by its oligomerization state, which affects its degradation rate. [21] Additionally, ubiquitination, mediated by E3 ligases like Parkin, targets proteins for proteasomal degradation, a mechanism that fine-tunes the abundance of various enzymes and signaling molecules involved in maintaining lipid homeostasis. [22] These regulatory layers ensure that lipid synthesis and breakdown are precisely adapted to cellular needs and environmental cues.
Metabolic Integration and Disease Relevance
Section titled “Metabolic Integration and Disease Relevance”The pathways governing eicosenoyl sphingomyelin and other lipids operate within a highly integrated metabolic network, where dysregulation can lead to significant physiological consequences. Genetic variants across numerous loci collectively contribute to the complex etiology of polygenic dyslipidemia, influencing plasma levels of various lipids, including cholesterol and triglycerides.[1] These genetic predispositions can alter the homeostasis of key lipids, carbohydrates, and amino acids, ultimately shaping an individual’s metabolic phenotype. [11]
Dysregulation within these interconnected lipid pathways is a central mechanism underlying metabolic disorders. Imbalances in lipid metabolism, often stemming from genetic factors affecting the function or regulation of enzymes and transporters, are significant contributors to conditions like hyperlipidemia and cardiovascular diseases.[1] Understanding the intricate interplay between genetic variations, metabolic pathways, and their emergent properties is crucial for identifying novel therapeutic targets and developing personalized strategies to prevent and manage lipid-related diseases.
References
Section titled “References”[1] Kathiresan S et al. “Common variants at 30 loci contribute to polygenic dyslipidemia.” Nat Genet, vol. 40, no. 12, 2008, pp. 1417–1424.
[2] O’Donnell, Christopher J., et al. “Genome-wide association study for subclinical atherosclerosis in major arterial territories in the NHLBI’s Framingham Heart Study.”BMC Med Genet, vol. 8 Suppl 1, 2007, pp. S11.
[3] Yang, Qiong, et al. “Genome-wide association and linkage analyses of hemostatic factors and hematological phenotypes in the Framingham Heart Study.”BMC Med Genet, vol. 8 Suppl 1, 2007, pp. S12.
[4] Willer CJ et al. “Newly identified loci that influence lipid concentrations and risk of coronary artery disease.”Nat Genet, vol. 40, no. 2, 2008, pp. 161–169.
[5] Yuan, Xin, et al. “Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes.” Am J Hum Genet, vol. 83, no. 4, 2008, pp. 520-28.
[6] Aulchenko, Yurii S., et al. “Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts.”Nat Genet, vol. 41, no. 1, 2009, pp. 47-55.
[7] Pare, Guillaume, et al. “Novel association of ABO histo-blood group antigen with soluble ICAM-1: results of a genome-wide association study of 6,578 women.” PLoS Genet, vol. 4, no. 7, 2008, pp. e1000118.
[8] Benjamin EJ et al. “Genome-wide association with select biomarker traits in the Framingham Heart Study.” BMC Med Genet, 2007.
[9] Vasan, Ramachandran S., et al. “Genome-wide association of echocardiographic dimensions, brachial artery endothelial function and treadmill exercise responses in the Framingham Heart Study.”BMC Med Genet, vol. 8 Suppl 1, 2007, pp. S2.
[10] Melzer, David, et al. “A genome-wide association study identifies protein quantitative trait loci (pQTLs).” PLoS Genet, vol. 4, no. 5, 2008, pp. e1000072.
[11] Gieger C et al. “Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum.”PLoS Genet, vol. 4, no. 11, 2008, e1000282.
[12] Sabatti, C. et al. “Genome-wide association analysis of metabolic traits in a birth cohort from a founder population.”Nature Genetics, vol. 40, no. 12, Dec. 2008, pp. 1392-1402.
[13] Vance JE. “Membrane lipid biosynthesis.” Encyclopedia of Life Sciences, John Wiley & Sons, Ltd: Chichester, 2001.
[14] Schaeffer L et al. “Common genetic variants of the FADS1 FADS2 gene cluster and their reconstructed haplotypes are associated with the fatty acid composition in phospholipids.” Hum Mol Genet, vol. 15, 2006, pp. 1745–1756.
[15] Toomey, R. E., and S. J. Wakil. “Studies on the mechanism of fatty acid synthesis. XVI. Preparation and general properties of acyl-malonyl acyl carrier protein-condensing enzyme from Escherichia coli.” J Biol Chem, vol. 241, no. 5, 1966, pp. 1159–1165.
[16] Pollin, Timothy I., et al. “A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection.” Science, vol. 322, no. 5900, 2008, pp. 1702–1705.
[17] Yoshida K et al. “Angiopoietin-like protein 4 is a potent hyperlipidemia-inducing factor in mice and inhibitor of lipoprotein lipase.”J. Lipid Res., vol. 43, 2002, pp. 1770–1772.
[18] Burkhardt R et al. “Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13.” Arterioscler Thromb Vasc Biol., 2008.
[19] Aalto-Setala K et al. “Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles.”J. Clin. Invest., vol. 90, 1992, pp. 1889–1900.
[20] Wilson PA et al. “Characterization of the human patatin-like phospholipase family.” J. Lipid Res., vol. 47, 2006, pp. 1940–1949.
[21] Cheng HH et al. “Oligomerization state influences the degradation rate of 3-hydroxy-3-methylglutaryl-CoA reductase.” J Biol Chem, vol. 274, 1999, pp. 17171–17178.
[22] Kahle PJ, Haass C. “How does parkin ligate ubiquitin to Parkinson’s disease?”EMBO Rep, vol. 5, 2004, pp. 681–685.